TLDR
- Centene shares plummeted 14% on Tuesday, recording the steepest decline among all S&P 500 constituents
- Affordable Care Act membership projected to fall to 3.5 million members by Q1 close, a significant drop from December’s 5.5 million
- Management maintained adjusted EPS forecast of over $3 for fiscal 2026
- Mizuho analysts reduced their price target from $47 down to $41 while keeping a Neutral stance
- Medicare Advantage segment continues operating in negative territory and won’t achieve break-even status until at least 2027
Investors in Centene have faced challenging conditions this year, and Tuesday’s trading session only intensified the pain. The healthcare insurance provider saw its shares crater 14% following CEO Sarah London’s presentation at the Barclays Global Healthcare Conference, where her remarks about membership losses sent shockwaves through the market.
During her conference appearance, London informed investors that Centene’s three primary business segments continue progressing toward 2026 targets. She reiterated the company’s adjusted earnings forecast of more than $3 per share — aligning precisely with the $3 consensus from FactSet’s analyst survey.
However, the market response was far from enthusiastic. Without any positive surprises in the guidance, investors fixated on concerning enrollment trends.
The healthcare insurer now projects approximately 3.5 million Affordable Care Act marketplace participants by the conclusion of Q1, representing a substantial decline from December’s 5.5 million figure. February data showed enrollment at 3.6 million members.
London indicated the company had forecasted industry-wide contraction “somewhere between the high teens and the mid-thirties” on a percentage basis. She noted Centene anticipated landing “at the higher end of that and possibly higher than the top end of that.”
She explained that strategic pricing adjustments implemented at the year’s beginning contributed to the membership decline, as Centene chose to emphasize profitability enhancement rather than enrollment expansion.
Medicare Advantage Still a Drag
The company’s Medicare Advantage operations remain a persistent challenge. This segment operated at negative margins throughout 2025 and is projected to stay marginally unprofitable during 2026, with management targeting break-even status by 2027.
Additional uncertainty stems from the pending final rate determination from the Centers for Medicare and Medicaid Services, scheduled for release no later than April 6. The Trump administration’s earlier proposal to maintain essentially flat Medicare reimbursement rates for 2027 negatively impacted Centene and industry competitors.
London confirmed the organization provided feedback to CMS regarding the Advance Rate Notice and voiced optimism that final rates would more accurately account for current medical cost patterns throughout the sector.
Analyst Reaction
Mizuho responded swiftly following the conference presentation. The investment firm lowered its Centene price objective to $41 from the previous $47 while maintaining its Neutral recommendation.
Mizuho highlighted worries surrounding health insurance exchange member attrition and specialty pharmaceutical cost pressures. The firm indicated it’s implementing a more cautious valuation approach pending improved visibility on enrollment deterioration.
Truist Securities adopted a more bullish perspective, preserving its Buy recommendation with a $49 target price, emphasizing margin expansion potential and management’s confidence level. Cantor Fitzgerald maintained a Neutral position with a $41 target, characterizing the 2026 operational landscape as difficult.
For perspective, Centene has declined 9.7% during 2026, compared to the S&P 500’s 0.7% retreat.
The stock has nevertheless outperformed several industry peers. Molina Healthcare has fallen 17% year-to-date, Elevance Health is down 18%, and UnitedHealth Group has declined 14%.
Centene’s fourth quarter 2025 results revealed an adjusted diluted loss of $1.19 per share, which slightly exceeded expectations of a $1.22 loss. Revenue reached $49.73 billion, surpassing the anticipated $48.39 billion.
InvestingPro calculates Centene’s fair valuation at $62.11, with Wall Street analysts forecasting EPS of $3.05 for complete fiscal year 2026.
